286 related articles for article (PubMed ID: 37355629)
21. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
22. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
23. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin.
Ranallo N; Bocchini M; Menis J; Pilotto S; Severi S; Liverani C; Bongiovanni A
Expert Rev Anticancer Ther; 2022 Jun; 22(6):597-603. PubMed ID: 35477310
[TBL] [Abstract][Full Text] [Related]
24. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J; Egusa EA; Wang S; Badura ML; Lee F; Bidkar AP; Zhu J; Shenoy T; Trepka K; Robinson TM; Steri V; Huang J; Wang Y; Small EJ; Chan E; Stohr BA; Ashworth A; Delafontaine B; Rottey S; Cooke KS; Hashemi Sadraei N; Yu B; Salvati M; Bailis JM; Feng FY; Flavell RR; Aggarwal R
Cancer Res; 2023 Jan; 83(2):301-315. PubMed ID: 36351060
[TBL] [Abstract][Full Text] [Related]
26. Harnessing DLL3 inhibition: From old promises to new therapeutic horizons.
Cortinovis DL; Colonese F; Abbate MI; Sala L; Meazza Prina M; Cordani N; Sala E; Canova S
Front Med (Lausanne); 2022; 9():989405. PubMed ID: 36530878
[TBL] [Abstract][Full Text] [Related]
27. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
28. Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma.
Xie H; Kaye FJ; Isse K; Sun Y; Ramoth J; French DM; Flotte TJ; Luo Y; Saunders LR; Mansfield AS
Oncologist; 2020 Sep; 25(9):810-817. PubMed ID: 32372416
[TBL] [Abstract][Full Text] [Related]
29. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
30. Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
Matsuo K; Taniguchi K; Hamamoto H; Inomata Y; Komura K; Tanaka T; Lee SW; Uchiyama K
Cancer Sci; 2021 Aug; 112(8):2984-2992. PubMed ID: 34107132
[TBL] [Abstract][Full Text] [Related]
31. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
[TBL] [Abstract][Full Text] [Related]
32. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
33. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.
Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC
Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513
[TBL] [Abstract][Full Text] [Related]
34. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
35. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
Immunology; 2024 Mar; ():. PubMed ID: 38469682
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Zhang Y; Tacheva-Grigorova SK; Sutton J; Melton Z; Mak YSL; Lay C; Smith BA; Sai T; Van Blarcom T; Sasu BJ; Panowski SH
Clin Cancer Res; 2023 Mar; 29(5):971-985. PubMed ID: 36692420
[TBL] [Abstract][Full Text] [Related]
37. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress.
Yang W; Wang W; Li Z; Wu J; Huang X; Li J; Zhang X; Ye X
Crit Rev Oncol Hematol; 2023 Nov; 191():104136. PubMed ID: 37716517
[TBL] [Abstract][Full Text] [Related]
38. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Johnson ML; Zvirbule Z; Laktionov K; Helland A; Cho BC; Gutierrez V; Colinet B; Lena H; Wolf M; Gottfried M; Okamoto I; van der Leest C; Rich P; Hung JY; Appenzeller C; Sun Z; Maag D; Luo Y; Nickner C; Vajikova A; Komarnitsky P; Bar J
J Thorac Oncol; 2021 Sep; 16(9):1570-1581. PubMed ID: 33823285
[TBL] [Abstract][Full Text] [Related]
39. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
[TBL] [Abstract][Full Text] [Related]
40. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.
Lashari BH; Vallatharasu Y; Kolandra L; Hamid M; Uprety D
Drugs R D; 2018 Dec; 18(4):255-258. PubMed ID: 30232719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
